PURPOSE: The best screening practice for @entity4309 ( @entity4309 ) in @entity1204 ( @entity1204 ) remains unknown. We sought to determine whether @entity5 @entity124 ( @entity124 ) typing along with immunohistochemistry (IHC) and @entity6756 methylation analysis can help identify @entity1 with @entity4309 . @entity1 AND METHODS: ECs from GOG210 @entity1 were assessed for @entity124 , @entity6756 methylation, and mismatch repair (MMR) protein expression. Each @entity5 was classified as having normal MMR, defective MMR associated with @entity6756 methylation, or probable MMR mutation (ie, defective MMR but no methylation). @entity5 family history and demographic and clinical features were compared for the three groups. Lynch mutation testing was performed for a subset of @entity1 . RESULTS: Analysis of 1,002 ECs suggested possible MMR mutation in 11.8% of @entity5 . The number of @entity1 with a family history suggestive of @entity4309 was highest among @entity1 whose @entity5 were classified as probable MMR mutation (P = .001). Lynch mutations were identified in 41% of @entity1 cases classified as probable mutation (21 of 51 tested). One of the @entity4638 Lynch mutations was identified in a @entity1 whose @entity5 had intact @entity4638 expression. Age at diagnosis was younger for mutation carriers than noncarriers (54.3 v 62.3 years; P < .01), with five carriers diagnosed at age > 60 years. CONCLUSION: Combined @entity124 , methylation, and IHC analysis may prove useful in Lynch screening in @entity1204 . Twenty-four percent of mutation carriers presented with ECs at age > 60 years, and one carrier had an @entity5 with no IHC defect. Restricting Lynch testing to @entity1 diagnosed at age < 60 years or to @entity1 with @entity154 could result in missing a substantial fraction of @entity74 .

Combined Microsatellite Instability, @entity6756 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in XXXX From GOG210: An NRG Oncology and Gynecologic Oncology Group Study.

@entity1204 :: ('MESH:D016889', 'Disease') :: ['endometrial cancer', 'EC'] @entity6756 :: ('4292', 'Gene') :: ['MLH1'] @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient', 'PATIENTS'] @entity124 :: ('MESH:D053842', 'Disease') :: ['MSI', 'microsatellite instability'] @entity154 :: ('MESH:D000013', 'Disease') :: ['IHC defects'] @entity4309 :: ('MESH:D003123', 'Disease') :: ['Lynch syndrome', 'LS'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'MSI-positive tumor', 'Cancer', 'tumors'] @entity74 :: ('MESH:D030342', 'Disease') :: ['genetic disease'] @entity4638 :: ('2956', 'Gene') :: ['MSH6']
@entity1204 :: (MESH:D016889,Disease) :: ['Endometrial Cancers']
